Indivior PLC (NASDAQ:INDV – Get Free Report) declared a special dividend on Thursday, September 17th. Stockholders of record on Friday, October 30th will be paid a dividend of 8.13 per share on Friday, November 6th. The ex-dividend date is Friday, October 30th.
Indivior Trading Down 2.3%
Indivior stock opened at $34.88 on Friday. The firm has a market cap of $4.12 billion, a P/E ratio of 12.50 and a beta of 0.82. Indivior has a 1-year low of $22.30 and a 1-year high of $42.81. The firm has a 50-day moving average of $37.58 and a 200-day moving average of $36.09.
Indivior (NASDAQ:INDV – Get Free Report) last announced its quarterly earnings results on Tuesday, June 30th. The company reported $5.75 earnings per share (EPS) for the quarter. Indivior had a negative return on equity of 283.11% and a net margin of 26.65%.The company had revenue of $343.00 million for the quarter. Research analysts forecast that Indivior will post 3.66 earnings per share for the current fiscal year.
Indivior Company Profile
Indivior plc is a specialty pharmaceutical company focused on developing and commercializing medicines for addiction and serious mental health disorders. Its portfolio is primarily centered on treatments for opioid use disorder, with an emphasis on products designed to support recovery, reduce illicit opioid use and address the risk of overdose.
The company’s key products include SUBOXONE sublingual film, a buprenorphine-and-naloxone treatment for opioid use disorder; SUBLOCADE, a long-acting injectable form of buprenorphine; and OPVEE, a nalmefene nasal spray intended for the emergency treatment of opioid overdose.
Featured Stories
- Five stocks we like better than Indivior
- MarketBeat Week in Review – 09/14 – 09/18
- J.B. Hunt’s Stock Plunges After Market Misprices Profit Warning
- 2 Stocks Breaking Out Post-FOMC With One Thing in Common
- Lennar’s Q3 Miss Hides a Stronger Operating Story Beneath the Housing Slump
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.
